Drilldown: Medicines
Medicines > onset 
:
1–2 h or
5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal or
BP and symptomatic LUTS improvement within 1-2 weeks
:
1–2 h or
5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal or
BP and symptomatic LUTS improvement within 1-2 weeks Use the filters below to narrow your results.
generic:
brand:
classes:
Beta Blocker (2) ·
Cardioselective (β1) (1) ·
Cardioselective (β1) + vasodilator (1) ·
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Analgesics|Analgesic]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2) ·
[[:Category:Opioid analgesics|Opioid analgesic (natural phenanthrene from opium poppy)]] (1) ·
[[:Category:Schedule II controlled substances|Schedule II controlled substance]] (1)
mechanism:
None (2) ·
Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
starting dose:
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) ·
5 mg daily (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1) ·
IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols (1)
preparations:
1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) ·
1, 2, 5, 10 mg capsules and tablets (1) ·
2.5, 5, 10, 20 mg tabs (1) ·
5, 10 mg tabs (1) ·
IR tablets 15, 30 mg; oral solution 10 mg/5 mL, 20 mg/mL, 100 mg/5 mL (concentrated); suppositories; ER tablets and capsules in multiple strengths; injectable 0.5-50 mg/mL (1)
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
9–12 h (1) ·
Morphine 2-4 hours; morphine-6-glucuronide active metabolite 2-4 hours (longer with renal impairment)'"`UNIQ--ref-00000020-QINU`"' (1) ·
~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) ·
~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) ·
~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1)
bioavailability:
pregnancy:
Category C (2) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.